Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of...

Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results
of Phase 2A Oral Insulin Capsule Clinical Trials

JERUSALEM, July 31 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc.
(OTCBB: ORMP) (http://www.oramed.com), a developer of oral delivery systems,
announced today that it will hold a conference call on August 6, 2008 at
10:30 AM EDT to present the results of its Phase 2A clinical trials of its
flagship product, ORMD 0801, an oral insulin capsule.
Oramed's Phase 2A trial is focused on assessing the safety and efficacy
of ORMD 0801. This study is a continuation of the successfully completed
Phase 1 studies in Israel. Interested parties should dial:
In the United States: +1-888-668-9141
All other locations: +972-3-918-0691
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top research scientists at Jerusalem's Hadassah
Medical Center. The Company's corporate and R&D headquarters are based in
Jerusalem.
For more information, please visit http://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks
and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's ability to
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of the company
to differ materially from those expressed or implied in such forward looking
statements. The company undertakes no obligation to update or revise any
forward-looking statements.
Company and Investor Relation Contacts:
Oramed Pharmaceuticals
Eric Rosenberg
Cell: +972-54-566-7713
Office: +972-2-566-0001
eric@oramed.com

Media Contacts:
Ruder Finn Israel for Oramed
Matthew Krieger
Cell: +972-54-467-6950
Office: +972-2-589-2003
matthew@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Company and Investor Relation Contacts: Oramed Pharmaceuticals, Eric
Rosenberg, Cell: +972-54-566-7713, Office: +972-2-566-0001, eric@oramed.com;
Media Contacts: Ruder Finn Israel for Oramed, Matthew Krieger, Cell:
+972-54-467-6950, Office: +972-2-589-2003, matthew@oramed.com